Abstract

Provided herein are methods and compositions for the diagnosis, prognosis, and treatment of dilated cardiomyopathy (DCM) and heart failure (HF). In particular, provided are methods and compositions for detecting a loss-of-function mutation in the CD36 gene. Provided are methods of determining the likelihood that a subject will respond to a treatment for DCM or HF, based on the identification of a CD36 mutation in a sample from the subject.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Disclosed are methods of deriving the amount of a free ligand or lipophilic hormone in a sample based on a series of measurements that allow for the amount of free ligand or lipophilic hormone to be derived.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/78 - Thyroid gland hormones
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Abstract

This present disclosure provides devices, systems, and methods for the treatment of conditions pertaining to bladder control. In particular, the present disclosure provides devices, systems, and methods directed to the application of electrical stimulation to the proximal urethra and associated nervous tissue to elicit voiding contractions that normalize bladder function.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode

Abstract

Disclosed are compositions comprising adipose stem cell (ASC) derived exosomes. Disclosed are lyophilized compositions comprising adipose stem cell (ASC) derived exosomes. Disclosed are methods of treating a wound comprising administering a composition comprising one or more adipose stem cell derived exosomes to a wound of a subject. Disclosed are methods of promoting wound healing comprising administering a composition comprising one or more adipose stem cell derived exosomes to a wound of a subject. Disclosed are methods of accelerating wound closure time comprising administering a composition comprising one or more adipose stem cell derived exosomes to a wound of a subject. Disclosed are methods of reducing oxidative stress in a human dermal fibroblasts (HDF) comprising contacting an HDF with a composition comprising one or more adipose stem cell derived exosomes. Disclosed are methods of increasing cell viability in a subject comprising administering a composition comprising one or more adipose stem cell derived exosomes to the subject.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

Disclosed herein, are hammerhead ribozymes that bind to a target mRNA comprising a NUH ribozyme cleavage site that have enhanced turnover rates. Also described herein, are methods of administering hammerhead ribozymes that bind to a target mRNA comprising a NUH ribozyme cleavage site to treat eye diseases.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Disclosed herein is a method of treating pain, such as, for example, chronic lower back pain. One or more electrodes can be positioned proximate to a spinal cord. Using the one or more electrodes, a transdermal stimulation routine can be applied to a portion of the spinal cord to treat pain.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising

Abstract

CD36CD36CD36 mutation in a sample from the subject.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

(0199] Provided herein are methods and compositions for the diagnosis, prognosis, and treatment of cancer therapy-related cardiac dysfunction (CTRCD). In particular, provided are methods and compositions for detecting a loss-of-function mutation in the CD36 gene. Provided are methods of determining the likelihood that a subject will respond to a treatment for CTRCD, based on the identification of a CD36 mutation in a sample from the subject.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present disclosure provides engineered mitochondria and antibody-mitochondrion conjugates for targeted delivery to cells. The present disclosure also provides methods for using the engineered mitochondria and antibody-mitochondrion conjugates for treating a cardiovascular disease (CVD) or mitochondrial dysfunction (mt-dys) in a subject.

IPC Classes  ?

• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

Disclosed herein are anti-Klebsiella pneumonia sequence type 258 wzi50, wzi154, or wzi29 capsular polysaccharide antibodies useful in inhibiting, treating or preventing Klebsiella pneumonia ST258 infections in a subject.

IPC Classes  ?

• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

This disclosure relates to nucleobase polymers useful for degrading GATA-3 mRNA. In certain embodiments, this disclosure relates to nucleobase polymers and nanoparticles conjugated to nucleobase polymers disclosed herein. In certain embodiments, the nucleobase polymers or nanoparticles can be used in methods of managing disorders associated with excessive GATA-3 expression in inflammatory disorders and respiratory disorders such as asthma.

IPC Classes  ?

• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/51 - Nanocapsules
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/06 - Antiasthmatics
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Abstract

Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61B 5/245 - Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetoencephalographic [MEG] signals
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
• A61B 5/377 - Electroencephalography [EEG] using evoked responses
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/38 - Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
• A61N 2/00 - Magnetotherapy
• G01R 33/48 - NMR imaging systems
• G06N 20/00 - Machine learning
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
• G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

A pressure relief system for use with a wheelchair includes a backrest support including a plurality of backrest cells. The backrest cells include a base which includes a plurality of air ports, a cover in connection with the base, and resilient elements within an interior of the backrest cells. The pressure relief system-further includes a seat support including a plurality of seat cells. The seat cells includes a base which includes a plurality of air ports, a cover in connection with the base, and resilient elements within an interior of the seat cells. The pressure relief system also includes a source of pressurize air in fluid connection with the air ports of each of the backrest cells and with the air ports of the seat cells via which the resilient elements within the backrest cells and the resilient elements within the seat cells are fluidizable.

IPC Classes  ?

• A61G 5/10 - Parts, details or accessories
• A61G 7/057 - Arrangements for preventing bed-sores or for supporting patients with burns, e.g. mattresses specially adapted therefor

Abstract

Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61B 5/245 - Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetoencephalographic [MEG] signals
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
• A61B 5/377 - Electroencephalography [EEG] using evoked responses
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/38 - Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
• A61N 2/00 - Magnetotherapy
• G01R 33/48 - NMR imaging systems
• G06N 20/00 - Machine learning
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
• G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

Mammals typically heal with fibrotic scars. Treatments to regenerate human skin and hair without a scar remain elusive. Mice lacking C-X-C motif chemokine receptor 2 (CXCR2-KO) displayed robust and complete tissue regeneration across three different injury models, including skin, hair follicle, and cartilage. Remarkably, wild type mice receiving plasma from CXCR2-KO mice through parabiosis or injections healed wounds scarlessly. A comparison of circulating proteins using multiplex ELISA revealed a 24-fold higher plasma level of granulocyte-colony stimulation factor (G-CSF) in CXCR2-KO blood. Local injections of G-CSF into WT mouse wound beds reduced scar formation and increased hair follicle regeneration by 6-fold. G-CSF directly polarized macrophages into an anti-inflammatory phenotype, and both CXCR2-KO and G-CSF-treated mice recruited more anti-inflammatory macrophages into injured areas. These results improve our molecular understanding of scarless tissue regeneration and introduce a new therapeutic approach for cutaneous wounds and hair regeneration. Provided are compositions and methods relating to treating wound healing pathologies.

IPC Classes  ?

• A61K 38/19 - CytokinesLymphokinesInterferons
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 36/53 - Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The present invention relates to methods of using cotinine to reduce negative effects of stress in cultured sea animals such as, for example, fish, krill, and crab. Examples of negative effects that can be reduced include, but are not limited to, duration of survival, weight loss, and skin infections. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

IPC Classes  ?

• A61K 31/465 - NicotineDerivatives thereof
• A61K 61/59 -
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants

Abstract

The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer such as, for example, a primary or secondary tumor within a subject's brain, breast, kidney, pancreas, lung, colon, prostate, lymphatic system, liver, ovary, or cervix. Additional examples of cancers for which the disclosed compounds and compositions can be useful include, but are not limited to, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanomas, gliomas, leukemia, lymphoma, chronic myeloproliferative disorders, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinomas, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

IPC Classes  ?

• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 35/00 - Antineoplastic agents
• C07D 257/04 - Five-membered rings
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Disclosed herein are rolled-membrane microfluidic diffusion devices and corresponding methods of manufacture. Also disclosed herein are three-dimensionally printed microfluidic devices and corresponding methods of manufacture. Optionally, the disclosed microfluidic devices can function as artificial lung devices.

IPC Classes  ?

• A61M 1/16 - Dialysis systemsArtificial kidneysBlood oxygenators with membranes
• A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
• B01D 63/00 - Apparatus in general for separation processes using semi-permeable membranes
• B01D 63/06 - Tubular membrane modules
• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
• B01D 69/04 - Tubular membranes
• B01D 69/12 - Composite membranesUltra-thin membranes
• B01D 71/70 - Polymers having silicon in the main chain, with or without sulfur, nitrogen, oxygen or carbon only

Abstract

An anti-PvAMA1 antibody, antibody fragment, antigen binding fragment thereof or vaccine for use in treating and/or preventing malaria as described herein.

IPC Classes  ?

• C07K 16/20 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 33/06 - Antimalarials
• C07K 14/445 - Plasmodium
• A61K 39/015 - Hemosporidia antigens, e.g. Plasmodium antigens

Abstract

Methods, systems, and apparatuses are provided for retinal distance-screening using machine learning.

IPC Classes  ?

• G06T 7/00 - Image analysis
• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
• G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
• G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing

Abstract

An apparatus for donning a compression garment includes a base having a platform extending along a longitudinal axis. A bladder has a wall defining an inner surface and an outer surface. The inner surface defines an interior volume. The wall is folded upon itself along a rolled end so that a first portion of the wall is surrounded by a second portion of the wall. An inlet port is in fluid communication with the interior volume of the bladder. The outer surface of the first portion of the wall defines a receiving space positioned within and surrounded by the outer surface of the first portion. At least a portion of the bladder is movable relative to the platform to permit the rolled end to change position along the wall of the bladder.

IPC Classes  ?

• A47G 25/90 - Devices for domestic use for assisting in putting-on or pulling-off clothing, e.g. stockings or trousers
• A61F 13/08 - Elastic stockingsBandages or dressingsAbsorbent pads specially adapted for feet or legsCorn-padsCorn-rings for contracting aneurisms

Abstract

The present disclosure is concerned with small molecule modulators of KLF15 signaling useful for treating various disorders such as, for example, kidney disease (e.g., chronic kidney disease), heart disease, obesity, or a neurodegenerative disorder (e.g., amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

IPC Classes  ?

• C07D 213/85 - Nitriles in position 3
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• C07C 321/20 - Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
• C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Abstract

Systems and methods for assessing glaucoma loss using optical coherence topography. One method according to an aspect comprises receiving optical coherence image data and assessing functional glaucoma damage from retinal optical coherence image data. In an aspect, the systems and methods can map regions and layers of the eye to determine structural characteristics to compare to functional characteristics.

IPC Classes  ?

• G06T 7/00 - Image analysis
• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
• A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes

Abstract

An example method includes establishing a wireless link between a mobile device and an optical coherence tomography (OCT) test system, which includes a wireless interface. The method also includes executing an application on the mobile device to present a graphical user interface on a display of the mobile device. The method also includes sending instructions from the mobile device through the wireless link to activate the OCT test system to record OCT measurements for an OCT scan of at least one eye. The method also includes receiving OCT test data at the mobile device from the OCT test system through the wireless link. The OCT test data can represent the OCT measurements recorded by the OCT test system for the OCT scan of the at least one eye.

IPC Classes  ?

• A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06F 3/0484 - Interaction techniques based on graphical user interfaces [GUI] for the control of specific functions or operations, e.g. selecting or manipulating an object, an image or a displayed text element, setting a parameter value or selecting a range
• H04W 76/14 - Direct-mode setup
• H04W 76/30 - Connection release
• H04W 88/06 - Terminal devices adapted for operation in multiple networks, e.g. multi-mode terminals

Abstract

Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol/high lipids, and various inflammatory diseases and conditions.

IPC Classes  ?

• A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
• A61K 8/63 - SteroidsDerivatives thereof
• A61K 8/73 - Polysaccharides
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 31/724 - Cyclodextrins
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/06 - Antihyperlipidemics
• A61P 17/06 - Antipsoriatics
• A61P 31/04 - Antibacterial agents
• A61Q 19/00 - Preparations for care of the skin
• C07J 31/00 - Normal steroids containing one or more sulfur atoms not belonging to a hetero ring

Abstract

Controlled delivery compositions and methods that enhance wound closure and reduce fibrotic scarring are described. The methods include treating a wound in a subject by administering to the subject a therapeutically effective amount of a first agent that promotes wound closure and a therapeutically effective amount of a second agent that inhibits scarring. The controlled delivery compositions include a therapeutically effective amount of a first agent that promotes wound closure and a therapeutically effective amount of a second agent that inhibits scarring. The controlled delivery compositions permit rapid release of the first agent and delayed release of the second agent.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/19 - CytokinesLymphokinesInterferons
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

Disclosed herein are compositions comprising nanoliposomes useful for the treatment and prevention of stroke.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Recombinant vectors operably encoding a CR2-FH fusion protein comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising the recombinant vector, are described. Also provided are methods of using the compositions for treatment eye diseases such as macular degeneration or glaucoma.

IPC Classes  ?

• C12N 15/861 - Adenoviral vectors
• A61P 27/06 - Antiglaucoma agents or miotics
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

The present invention includes a method of fabricating a tissue engineered spinal tract, the method comprising (a) seeding a plurality of optogenetic neural cells at each end of a hydrogel microcolumn to form a construct; and (b) culturing the construct in vitro while stimulating the plurality of optogenetic neural cells with a predetermined wavelength of light.

IPC Classes  ?

• A61L 27/38 - Animal cells
• A61L 27/26 - Mixtures of macromolecular materials
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• C07K 14/405 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from algae
• C08L 5/08 - ChitinChondroitin sulfateHyaluronic acidDerivatives thereof
• C08L 5/12 - Agar-agarDerivatives thereof
• C08L 89/06 - Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin
• C12N 5/0793 - Neurons
• C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
• C12N 15/86 - Viral vectors

Abstract

Porous microcarriers prepared from a poly(lactide-co-glycolide) and a porogen, which are suitable for loading of therapeutic lipid nanoparticles into the pores thereof.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/51 - Nanocapsules
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

Systems and methods can facilitate wide broad-band IVUS for peripheral vascular applications with simultaneous improved resolution and penetration depth. A custom analog front end interface can withstand large voltages and recover to receive a sub-mV pulse from less than one mm away. The custom analog front end interface can be on an interface chip that can be sized to be integrated within a tip of the IVUS catheter to connect micro-cables within the IVUS catheter to the broad-band transducer. The interface chip can also include a dual-stage amplifier having a pulse mode configured to withstand voltage pulses greater than 30 VPP during pulsing and an echo reception mode configured to receive sub-mV echoes during echo reception.

IPC Classes  ?

• A61B 8/12 - Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
• G01S 7/52 - Details of systems according to groups , , of systems according to group

Abstract

Methods, systems, and apparatuses are described for a remote fetal sensor device. For example, the remote fetal sensor device may detect a first signal measurement from a first sensor device and a second signal measurement from a second sensor device. For example, the first signal measurement may be indicative of a first parameter. The second signal measurement may be indicative of a second parameter. Based on at least one of the first parameter or the second parameter, a contractile event indicative of a uterine contraction for a pregnant person may be determined.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

Described herein are compositions and methods for treating or preventing an injury associated with transplant. Specifically, the disclosure provides a composition for treating or preventing an injury associated with transplantation, comprising (a) a targeted inhibitor molecule wherein the targeted inhibitor molecule comprises a targeting portion and an inhibitor portion, wherein the molecule inhibits complement pathways, and (b) a sub-therapeutic dose of an immunosuppressant agent. Further provided are methods of treating or preventing an injury associated with transplantation with activated complement by using the compositions.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/13 - Cyclosporins
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The present invention provides an encapsulated gas or partial vacuum particle contrast media for use in CT imaging. In an exemplary embodiment, the invention provides an enteric contrast medium formulation. An exemplary formulation comprises, (a) an enteric contrast medium comprising a encapsulated gas or partial vacuum particle suspended in water. Exemplary encapsulated gas or partial vacuum particle has a specific gravity between 0.2 and 1.5. In various embodiments, the encapsulated gas or partial vacuum particle is suspended in aqueous media by an agent compatible with enteric administration of the formulation to a subject in need of such administration. In an exemplary embodiment, the contrast material is incorporated into a pharmaceutically acceptable carrier in which the material is suspended homogeneously. In an exemplary embodiment, the encapsulated gas or partial vacuum particle comprises 5% or more of the weight of the contrast material formulation. The invention also provides methods for imaging of the abdomen by dual energy CT or spectral CT contemporaneously with the delivery of the encapsulated gas or partial vacuum particle contrast material into the bowel lumen with or without the delivery of a second complementary contrast material into the blood vessels or other body compartments. The invention also provides methods for the digital separation of CT signal produced by the contrast media of the invention from the CT signal produced by other contrast media or bodily tissues to generate multiple resultant CT images with the contrast medium of the invention subtracted or highlighted.

IPC Classes  ?

• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• A61B 6/03 - Computed tomography [CT]
• A61K 9/10 - DispersionsEmulsions
• A61K 9/50 - Microcapsules
• A61K 49/04 - X-ray contrast preparations

Abstract

A system for providing photodynamic therapy includes an assembly that is at least partially insertable into a patient. The assembly includes a catheter having an insertional end portion. The catheter is configured to permit positioning of the insertional end portion at a treatment site of an artery having an interior wall surface. At least one light emitting structure is coupled to the insertional end portion of the catheter. The assembly is configured to position the at least one light emitting structure at or against the interior wall surface of the artery.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61M 25/10 - Balloon catheters
• A61N 5/067 - Radiation therapy using light using laser light

Abstract

Water-soluble conjugates of verteporfin are provided, which find therapeutic use, including by topical administration. Also provided are liposomal verteporfin formulations, which may be admixed with biomolecules such as hyaluronic acid.

IPC Classes  ?

• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
• A61K 9/51 - Nanocapsules
• A61P 27/02 - Ophthalmic agents

Abstract

Electrospun nanofiber membranes are provided. The membranes are electrospun from a suitable biocompatible and biodegradable biopolymer, e.g. gelatin, collagen, etc., to generate a membrane, which is then cross-linked. The membrane may be seeded with cells. The compositions find use tissue regeneration, particularly in repair, regeneration, and/or reconstruction of lamellar or partial defects of wounded corneal tissue.

IPC Classes  ?

• D01D 5/00 - Formation of filaments, threads, or the like
• A61F 2/14 - Eye parts, e.g. lenses or corneal implantsArtificial eyes
• A61L 27/14 - Macromolecular materials

Abstract

The present invention provides methods for treating reperfusion edema in patients who have suffered a stroke, the methods comprising administering an effective amount of one or more inhibitors of sodium D-glucose cotransporter 2 (SGLT2). The invention further contemplates administration of SGLT2 inhibitors in combination with recombinant tissue plasminogen activator (rt-PA). Exemplary SGLT2 inhibitors include canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, re-mogliflozin etabonate, sergliflozin etabonate, sotagliflozin, tofogliflozin and combinations thereof.

IPC Classes  ?

• A61K 38/49 - UrokinaseTissue plasminogen activator
• A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
• A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
• A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Methods, systems, and apparatuses are described for outputting a personalized humanoid avatar of a subject within a virtual environment to assist in the management of phantom limb pain in patients with limb amputations. Motion data associated with one or more motions of at least one intact limb of the subject may be received from a sensor. The motion data may be applied to an intact representation of a subject's amputated limb of the subject's avatar.

IPC Classes  ?

• A63F 13/55 - Controlling game characters or game objects based on the game progress
• A63F 13/428 - Processing input control signals of video game devices, e.g. signals generated by the player or derived from the environment by mapping the input signals into game commands, e.g. mapping the displacement of a stylus on a touch screen to the steering angle of a virtual vehicle involving motion or position input signals, e.g. signals representing the rotation of an input controller or a player's arm motions sensed by accelerometers or gyroscopes
• A63F 13/52 - Controlling the output signals based on the game progress involving aspects of the displayed game scene
• G02B 27/01 - Head-up displays
• G06T 13/40 - 3D [Three Dimensional] animation of characters, e.g. humans, animals or virtual beings
• G06T 19/00 - Manipulating 3D models or images for computer graphics
• G06T 19/20 - Editing of 3D images, e.g. changing shapes or colours, aligning objects or positioning parts

Abstract

Disclosed herein, are peptides that bind urokinase-type plasminogen activator receptors. The peptides may comprise amino acid sequences of IPPWEAPK (SEQ ID NO: 1), DLAQCQTPTQAAPPTPVSPR (SEQ ID NO: 2), or LHVPLMPAQPAPPK (SEQ ID NO: 3), or retro-inverso amino acid sequences of the above enumerated sequences. Also described herein, are methods of administering compounds comprising peptides that bind urokinase-type plasminogen activator receptors to subjects for the treatment of ovarian cancer and improving wound closure.

IPC Classes  ?

• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 35/00 - Antineoplastic agents

Abstract

Methods, systems, and apparatuses for predicting one or more neurological assessments or one or more cognitive scores associated with the observed movements of a subject. Motion data associated with movements of one or more subjects may be used to train a predictive model. The predictive model may be trained to output a prediction indicative of one or more neurological assessments or one or more cognitive scores of a subject.

IPC Classes  ?

• G06V 10/776 - ValidationPerformance evaluation
• G06T 7/00 - Image analysis
• G06T 7/246 - Analysis of motion using feature-based methods, e.g. the tracking of corners or segments
• G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G06V 40/20 - Movements or behaviour, e.g. gesture recognition

Abstract

Disclosed herein is dilator including a body having an outer surface, an insertional end, and an opposed second end. The body extends along a central axis. The outer surface defines a taper toward the insertional end between the second end and the insertional end. The body has a first major dimension in cross section in a first plane perpendicular to the central axis. The body has a second major dimension in cross section in a second plane perpendicular to the central axis. The second plane is spaced from the first plane by at least 3.5 cm along the central axis. The first plane is between the second plane and the insertional end of the body along the central axis. The body has a major dimension of less than the second major dimension in any plane perpendicular to the central axis between the first and second planes.

IPC Classes  ?

• A61M 29/00 - Dilators with or without means for introducing media, e.g. remedies
• A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
• A61M 25/06 - Body-piercing guide needles or the like
• A61M 25/08 - Advancing means, e.g. self-propelled

Abstract

The present invention provides an IL-33 decoy peptide comprising an amino acid sequence of a fragment of FLIL33 or a fragment of a FLIL33 variant, wherein the decoy peptide disrupts an association of FLIL33 with an FLIL33 binding partner.

IPC Classes  ?

• C07K 14/54 - Interleukins [IL]
• A61K 38/00 - Medicinal preparations containing peptides
• C12N 15/86 - Viral vectors

Abstract

An apparatus can be used for detecting acoustic signals of a vascular system. The apparatus can comprise at least one acoustic sensor. Each acoustic sensor can comprise a piezoelectric layer defining a first side and a second side, and a first annular electrode disposed on the first side of the piezoelectric layer. The first annular electrode can define a hole therethrough. A second annular electrode can be disposed on the second side of the piezoelectric layer disposed against the second. A polymer engagement layer can be positioned against the first side of the piezoelectric layer and disposed at least partially within the hole of the first annular electrode. Methods of data processing for data collected via the apparatus are also disclosed herein.

IPC Classes  ?

• A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation

Abstract

The present disclosure is concerned with methods of treating disorders associated with overactivation of IKKβ such as, for example, cancer, arthritis, a cardiometabolic disease, and chronic obstructive pulmonary disease (COPD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

IPC Classes  ?

• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/4245 - Oxadiazoles
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/69 - Boron compounds
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

C. difficile is a leading cause of antibiotic-associated diarrhea and nosocomial infection in the United States. The symptoms of C. difficile infection (CDI) are associated with the production of two homologous protein toxins, TcdA and TcdB, and the toxins are considered bone fide targets for clinical diagnosis as well as the development of novel prevention and therapeutic strategies. Disclosed herein are nanobodies that bind specific structural and functional domains of TcdA and TcdB.

IPC Classes  ?

• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• A61P 31/04 - Antibacterial agents
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

Compounds that are selective inhibitors of Smad3 activation are disclosed. The compounds are (3-aryl-1,2,4-oxadiazol-5-yl)-3,4-dihydro-2H-pyrano[2,3-b]pyridines of the following structure: Compounds that are selective inhibitors of Smad3 activation are disclosed. The compounds are (3-aryl-1,2,4-oxadiazol-5-yl)-3,4-dihydro-2H-pyrano[2,3-b]pyridines of the following structure: Compounds that are selective inhibitors of Smad3 activation are disclosed. The compounds are (3-aryl-1,2,4-oxadiazol-5-yl)-3,4-dihydro-2H-pyrano[2,3-b]pyridines of the following structure: in which Ar is aryl or heteroaryl. The compounds disclosed are useful in treatment of fibrotic disease, particularly renal fibrosis, and similar diseases associated with the dysregulation of the HIPK2/Smad3 signaling pathway.

IPC Classes  ?

• C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

An apparatus for imaging a cavity. The apparatus comprises an enclosure, comprising a distal end, a proximal end, and a transparent portion therebetween. The proximal end comprises at least one electrical connection, and the transparent portion is transparent to an illumination signal; and a flexible tether, operably connected to the electrical connection of the proximal end of the enclosure. The enclosure further comprises an image acquisition device, an illumination source, and an annular reflector, wherein the illumination source is configured to generate the illumination signal comprising illumination beams, the annular reflector being configured to direct at least some of the illumination beams through the transparent portion of the enclosure at the cavity, thereby generating a reflected signal comprising reflected beams, the annular reflector being further configured to direct at least some of the reflected beams at the image acquisition device, the image acquisition device being configured to capture one or more images based on the reflected signal.

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
• A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements

Abstract

Methods and compositions are provided for the treatment of glaucoma and other optic neuropathies by administering an effective dose of an HDAC4 coding sequence or protein.

IPC Classes  ?

• C12N 9/80 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 27/06 - Antiglaucoma agents or miotics
• C12N 15/86 - Viral vectors

Abstract

A graphical user interface (GUI) for managing healthcare algorithms, wherein the GUI is configured to: simultaneously display (710), to a user, information associated with a number of models (410), wherein each of the number of models is configured to analyze a health metric of a patient; identify (720), to the user, an abnormal model from the number of models (440), wherein the abnormal model is operating outside a safety threshold (516); receive (730), from the user, input associated with the abnormal model (512); and cause (740) an action to be performed in response to receiving the input from the user.

IPC Classes  ?

• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
• G06N 20/00 - Machine learning
• G06F 3/048 - Interaction techniques based on graphical user interfaces [GUI]
• G16H 10/00 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data

Abstract

A firearm chamber safety flag for use with a firearm, safety flag including a body portion configured to be slidably received in the chamber of the firearm, a flag portion extending radially-outwardly from the body portion so that the flag portion is readily visible when the body portion; and a tag portion operably secured to the flag portion so that the tag portion is readily visible. The tag portion includes at least contact information related to suicide prevention services and may also include a message, photo, etc., as selected by the owner of the firearm.

IPC Classes  ?

• F41A 17/44 - Safety plugs, e.g. for plugging-up cartridge chambers

Abstract

A neural stimulation and recording electrode assembly includes a selectively deformable guide tube. The guide tube includes a plurality of sequentially coupled connecting structures, wherein each connecting structure of the plurality of connecting structures has a respective central axis, and wherein at least one of the plurality of connecting structures is selectively deformable relative to the central axis of a sequential connecting structure of the plurality of connecting structures such that the central axis of the selectively deformable connecting structure is angularly oriented relative to the central axis of the sequential connecting structure. The electrode assembly further includes an electrode subassembly having a central axis and a plurality of electrode contacts that are configured for selective radial movement about and between a retracted position and a deployed position, wherein in the deployed position, and relative to the central axis, each electrode contact is spaced radially outwardly from the retracted position.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61B 5/293 - Invasive
• A61N 1/375 - Constructional arrangements, e.g. casings

Abstract

An apparatus configured to dispense medication from a cartridge is disclosed. The apparatus includes a housing that is configured to couple to the cartridge. A piston is movable within the housing along a path of travel from a first position to a second position. A spring biases the piston toward the second position. A catch is configured to retain the piston in the first position. A trigger is configured to release the catch to permit the spring to move the piston to the second position. A sensor is configured to detect movement of the piston from the first position. A controller is in electrical communication with the sensor. The controller is configured to initiate a timer upon receiving a signal from the sensor indicative of movement of the piston from the first position.

IPC Classes  ?

• A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
• A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically

Abstract

The present application relates to a method for preventing or reducing cartilage loss joint damage and/or degeneration, and/or pain in a subject in need thereof, comprising administering to the subject an effective amount of an agent that reduces or inhibits a function or expression of Nav 1.7 protein.

IPC Classes  ?

• A61K 31/426 - 1,3-Thiazoles
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• G01N 33/487 - Physical analysis of biological material of liquid biological material
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

High accuracy selections of grouped elements can be achieved using a brain machine interface. A neural decoding system can: receive a neural signal from a neural recording device, identify that the neural signal is representative of the user at least thinking of attempting to perform a gesture, which is one of a plurality of known gestures mapped to a plurality of commands, and output a command based on the gesture (the gesture is mapped to the command). A controller can be in communication with the neural decoding system and a display. The controller can: receive the command, if the gesture is a primary gesture, then select a group to be an active group of elements, if the gesture is a secondary gesture, then at least select an element of the active group of elements and output a response indicative of the group being activated and/or the element being selected.

IPC Classes  ?

• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• G06F 3/0482 - Interaction with lists of selectable items, e.g. menus

Abstract

A firearm configured to be selectively discharged by a user is disclosed. The firearm includes a frame including a body portion, a grip, and a trigger guard extending from the body portion to the grip and defining a trigger space therebetween. The firearm further includes a firing mechanism including a trigger, the firing mechanism being disposed at least partially within the frame so that the trigger extends downwardly into the trigger space. The firearm further includes a locking mechanism having a blood alcohol sensor configured to determine or approximate a blood alcohol content of the user based on alcohol within perspiration of the user and a lock assembly configured to receive a control signal that is based on the determined or approximated blood alcohol content of the user. The lock assembly is configured to enable and disable the firing mechanism based upon the received control signal.

IPC Classes  ?

• F41A 17/06 - Electric or electromechanical safeties
• F41A 17/22 - Grip or stock safeties, i.e. safeties disengaged by clasping the grip or stock acting on the trigger

Abstract

Disclosed herein are methods and compositions for diagnosing cognitive fatigue. Specifically, the disclosure provides a method of diagnosing a subject as suffering from cognitive fatigue, which comprises measuring the amount of a biomarker, comprising phosphoglycerate kinase 1 (PGK1) and/or miR3185, in an exosome sample obtained from a saliva sample from the subject, comparing the amount with a control, and identifying the subject as suffering from cognitive fatigue.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/686 - Polymerase chain reaction [PCR]
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Sustained commands, such as drag and drop, scrolling, holding a position, and the like, can be performed by a user mentally controlling a controllable device via a brain-machine interface (BMI). Neural signals can be recorded by at least one neural recording device associated with a user and sent to the BMI, which can extract neural features from the neural signals. The BMI, which can include at least a Latch decoder, which can include a Gesture Type decoder and an Attempt decoder, can determine whether an action should be performed and a period of time the action should be held. If the action should be performed, then the controllable device can be controlled to perform the action for the period of time. If the action should not be performed, then the controllable device can be controlled to remain in a waiting state and/or a previous state.

IPC Classes  ?

• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer

Abstract

The present invention describes compositions and method for improving outcomes after injury to the central nervous system wherein complement signaling is activated. In one aspect, the method comprises administering to a subject a therapeutically effective amount of a therapeutic agent comprising a targeted inhibitor molecule comprising a targeting portion and an inhibitor portion, wherein the molecule inhibits complement, and wherein therapeutic agent is administered in combination with rehabilitation therapy or thrombolytic agent.

IPC Classes  ?

• A61K 38/57 - Protease inhibitors from animalsProtease inhibitors from humans
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/49 - UrokinaseTissue plasminogen activator
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 25/00 - Drugs for disorders of the nervous system
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

An ophthalmoscope for viewing an eye of a patient, including an optical device with a housing having a bottom window, a rear window, and a front wall including a reflective inner surface. A top wall may include a first portion, and a second portion wherein the first portion includes a reflective inner surface. A pair of side walls extends between side edges of the bottom window, the rear window, the top wall, and the front wall. The reflective inner surfaces of the top wall and the front wall are configured to direct light rays that enter the bottom window from the eye of the patient out of the rear window into the eyes of the ophthalmologist.

IPC Classes  ?

• A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
• A61B 90/50 - Supports for surgical instruments, e.g. articulated arms

Abstract

E. coli E. coli infection.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61P 31/04 - Antibacterial agents
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Irrigation solutions for endourological procedures in accordance with embodiments of the invention are illustrated. One embodiment includes an irrigation solution that includes saline and between 0.001 and 1.0 % w/v chitosan, where chitosan includes chitosan, a chitosan derivative, or a salt thereof. In some embodiments, the irrigation solution uses water or glycine instead of saline. In various embodiments, glycosaminoglycan is included to assist in healing. In many embodiments, chitosan solutions are used for sterilization.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 31/722 - ChitinChitosan
• A61K 31/74 - Synthetic polymeric materials
• A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters

Abstract

inter aliainter alia, are calcium sensing receptor agonists and uses thereof.

IPC Classes  ?

• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• A61K 33/44 - Elemental carbon, e.g. charcoal, carbon black
• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 249/06 - 1,2,3-TriazolesHydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
• C07D 307/81 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
• C07D 333/54 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• A61P 3/14 - Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
• A61P 11/06 - Antiasthmatics
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents

Abstract

Devices, methods, and kits are provided for measuring exophthalmos or enophthalmos. In particular, devices are provided for making either unilateral or bilateral measurements of exophthalmos or enophthalmos. The devices are designed for use during surgery with a patient in a supine position and are composed of a biocompatible metal, resin, or plastic that can withstand sterilization procedures. In addition, the devices can be produced inexpensively with a single-use design, which reduces the burden on sterile processing departments at hospitals, as a device may be discarded once a surgery is completed. The use of these devices will augment surgeons' qualitative visual estimations with quantitative measurements, which should make surgical procedures easier for surgeons to conduct and outcomes more precise and satisfactory for patients.

IPC Classes  ?

• A61B 3/107 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining the shape or measuring the curvature of the cornea
• A61B 5/107 - Measuring physical dimensions, e.g. size of the entire body or parts thereof
• A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions

Abstract

The present disclosure relates to apparatus, systems, and methods for detecting an altered physiological state in a subject. More particularly, the present disclosure relates to apparatus, systems, and methods for detecting a hypoglycemic state in a subject using volatile-organic-chemical biomarkers present in a sample of the subject's exhaled breath.

IPC Classes  ?

• G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath
• A61B 5/097 - Devices for facilitating collection of breath or for directing breath into or through measuring devices

Abstract

The present disclosure relates to systems and methods of identifying combinations of volatile-organic-compound (VOC) biomarkers where the combination of VOC biomarkers is reliable to selectively detect a physiological state in a subject. In an aspect, the present disclosure relates to solid-phase microextraction (SPME) fibers, and methods of fabricating such fibers.

IPC Classes  ?

• C08J 5/24 - Impregnating materials with prepolymers which can be polymerised in situ, e.g. manufacture of prepregs
• D01D 5/00 - Formation of filaments, threads, or the like
• D04H 1/728 - Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres characterised by the method of forming fleeces or layers, e.g. reorientation of fibres the fibres being randomly arranged by electro-spinning
• G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath
• B29C 70/08 - Fibrous reinforcements only comprising combinations of different forms of fibrous reinforcements incorporated in matrix material, forming one or more layers, with or without non-reinforced layers

Abstract

The present disclosure is concerned with magneto-patterned cell-laden hydrogel materials and methods of making and using those materials. The disclosed materials are useful for, among other things, repair of tissue defects, e.g., tissue at a tissue interface such as a bone-cartilage interface.

IPC Classes  ?

• A61L 27/38 - Animal cells
• A61L 27/04 - Metals or alloys
• A61L 27/22 - Polypeptides or derivatives thereof
• A61L 27/46 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
• A61L 27/52 - Hydrogels or hydrocolloids

Abstract

Disclosed are methods of detecting or quantifying a pathology -related or pathology-protective-pathway in a subject comprising combining a first ligand with a sample obtained from the subject comprising an extracellular particle, wherein the first ligand binds to a cell-type specific marker on the extracellular particle; combining a second ligand with the sample, wherein the second ligand binds to a pathology-related or pathology-protective pathway molecule on the extracellular particle; combining a donor bead to the sample, wherein the donor bead binds to the first ligand or second ligand; combining an acceptor bead to the sample, wherein the acceptor bead binds to the first ligand or second ligand, wherein the donor bead and acceptor bead do not bind to the same ligand; triggering the donor bead to activate the acceptor bead to produce a signal; wherein the amount, presence, or absence of a signal indicates the amount, presence, or absence of a pathological condition in the subject.

IPC Classes  ?

• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
• A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
• C12Q 1/6804 - Nucleic acid analysis using immunogens
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Provided are localized therapeutic delivery articles, comprising: a first fibrous layer comprising a first plurality of nanofibers; and a second fibrous layer comprising a second plurality of nanofibers, the first fibrous layer and the second fibrous layer being sealed to one another so as to define at least one sealed compartment therebetween, the article optionally comprising a first population of mechanically-responsive delivery particles configured to rupture upon exposure to a first rupture force, the first population of mechanically responsive delivery particles being disposed within at least one sealed compartment. The nanofibers can be aligned, which alignment allows the layers to emulate the structure of various body tissues, thereby affording control over cell growth on the articles. Also provided are methods of using and fabricating the disclosed articles.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 38/20 - Interleukins
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors

Abstract

The invention provides method for organizing the disinfection of one or more items contaminated with biological agent(s) comprising (a) attaching a radio-frequency ID (RFID) tag to an item(s) to be disinfected; exposing the item(s) of (a) to a disinfecting means for a period sufficient to disinfect the item; and (c) obtaining a signal from the tagged item when disinfection is complete thereby organizing the disinfection of one or more items.

IPC Classes  ?

• A61L 2/24 - Apparatus using programmed or automatic operation
• A61L 2/10 - Ultraviolet radiation
• A61L 2/20 - Gaseous substances, e.g. vapours
• G06K 7/10 - Methods or arrangements for sensing record carriers by electromagnetic radiation, e.g. optical sensingMethods or arrangements for sensing record carriers by corpuscular radiation
• G06Q 50/22 - Social work or social welfare, e.g. community support activities or counselling services
• G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation

Abstract

A composition, comprising: a hydrogel comprising crosslinked polymer chains, at least some of the crosslinked polymer chains having an agent coupled thereto. A method, comprising curing a precursor composition so as to give rise to a composition according to the present disclosure. A precursor composition, comprising: polymer chains bearing pendant groups; a crosslinker adapted to couple pendant groups to one another; and a functionalizer adapted to couple to a pendant group. A method, comprising curing a precursor composition according to the present disclosure so as to give rise to a composition, the composition optionally being a composition according to the present disclosure. A method, comprising: forming a hydrogel; and coupling the hydrogel to an agent, the coupling being effected by coupling (1) a pendant group borne by a polymer chain of the hydrogel and (2) a coupler associated with the agent.

IPC Classes  ?

• A61K 9/06 - OintmentsBases therefor
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Abstract

A disinfection system for a wheelchair may include an enclosure having a front wall, a rear wall, a top wall extending between a top edge of the front wall and a top edge of the rear wall, and an entry door pivotably secured to a side edge of either the front wall or the rear wall. At least one disinfection lamp is disposed within the enclosure and configured to disinfect the surface of the wheelchair stored therein (optionally, with UV-C light).

IPC Classes  ?

• A61L 2/10 - Ultraviolet radiation
• A61G 12/00 - Accommodation for nursing, e.g. in hospitals, not covered by groups , e.g. trolleys for transport of medicaments or foodPrescription lists
• A61L 2/24 - Apparatus using programmed or automatic operation
• A61L 2/26 - Accessories
• G08B 21/18 - Status alarms

Abstract

A wheelchair comprising a base assembly including a body portion having a frame and a plurality of wheel assemblies secured to the body portion. A seat assembly including a frame with a seating portion is supported on the base assembly, and a vertical lift assembly is secured to the base assembly and extends vertically upward therefrom. The vertical lift assembly is configured to move the seat assembly about and between a lowered vertical position and a raised vertical position. The lowered vertical position and the raised vertical position can be separated by at least 24.0 inches.

IPC Classes  ?

• A61G 5/10 - Parts, details or accessories
• A61G 5/04 - Chairs or personal conveyances specially adapted for patients or disabled persons, e.g. wheelchairs motor-driven

Abstract

The present invention provides methods for diagnosing a patient with emphysema, COPD of lung injury caused by tobacco use by detecting the levels of EMAP II in a sample. Disclosed herein are the hypervariable regions for a rat monoclonal antibody that binds to a form of EMAP II. This disclosure also includes a polypeptide sequence included in EMAP II that is the target for the binding of the antibody to its target protein. This epitope serves as the basis for a humanized antibody that can be used to treat patients that suffer from pathologies that exhibit elevated levels of EMAP II expression.

IPC Classes  ?

• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 11/00 - Drugs for disorders of the respiratory system
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

A system includes an eye tracker having a camera, the eye tracker being configured and arranged to track an eye movement of a subject, and a processor in communication with the eye tracker, the processor being configured and arranged to create a dataset of the eye movement, generate a plot of the dataset, the plot reflecting a timecourse of eye position versus time, and identify one or more streaking vertical lines in the plot to indicate a deficit in a cranial nerve function.

IPC Classes  ?

• A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/03 - Measuring fluid pressure within the body other than blood pressure, e.g. cerebral pressure

Abstract

A method of treating a patient includes tracking eye pupil movement of at least one of a first eye and a second eye of the patient using a device suitable for tracking eye pupil movement, analyzing eye pupil movement of the at least one of the first eye and the second eye of the patient using a computer in electronic communication with the device suitable for tracking eye pupil movement, generating a plot that reflects a trajectory traveled of each of the at least one of the first eye and the second eye in response to a visual stimuli, comparing eye pupil movement of the at least one of the first eye and the second eye of the patient to a normal or mean eye pupil movement, and calculating a plurality of velocities.

IPC Classes  ?

• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/107 - Measuring physical dimensions, e.g. size of the entire body or parts thereof
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present disclosure relates to a composition comprising Rifamycin SV and its use in the treatment of sarcopenia. More particularly, the present disclosure describes a pharmaceutical composition comprising Rifamycin SV for treating sarcopenia in subjects with a chronic disease.

IPC Classes  ?

• A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/33 - Heterocyclic compounds

Abstract

An electronic nasal cannula flame detector and oxygen shut-off device may include a nasal cannula with a pair of outlets, each outlet being configured for insertion into a nostril of the user. A flow tube has an inlet in fluid communication with the oxygen source and one outlet in fluid communication with the inlet of the cannula. An electronic shut-off valve is disposed in the flow tube and movable from a first position allowing oxygen flow to a second position preventing oxygen flow. A wire conductor provides power from a battery to maintain the electronic shut-off valve in the open position. A portion of the wire conductor extends across at least one outlet of the cannula and is configured to burn in the presence of fire.

IPC Classes  ?

• A61M 16/06 - Respiratory or anaesthetic masks
• A61M 16/20 - Valves specially adapted to medical respiratory devices

Abstract

The present disclosure relates, in general, to methods for treating a low CXCL9 or CXCL10 expressing cancer comprising administering to a subject having such cancer and in need thereof an effective amount of CXCL9, CXCL10 or the combination, in combination with an immune checkpoint inhibitor. The CXCL9, CXCL10 or combination may be administered as a polypeptide, a polynucleotide or as cells comprising a polynucleotide encoding CXCL9, CXCL10 or both. In one aspect, the treatment is amenable to patients with low or high mutational burden tumors.

IPC Classes  ?

• A61K 38/19 - CytokinesLymphokinesInterferons
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 14/52 - CytokinesLymphokinesInterferons
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/86 - Viral vectors
• C12N 5/0784 - Dendritic cellsProgenitors thereof
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection

Abstract

An assistive positioning device for supporting an arm of a patient includes a assembly secured to a support surface, and includes a base riser assembly rotatably mounted to the base. An upper arm assembly has a first end mounted to the base riser assembly and a second end. An elbow assembly rotatably serves a lower arm assembly to the upper arm assembly. A handle portion is served to a distant end of the low arm assembly. An entirety of the assistive positioning device can be free of magnetic metal.

IPC Classes  ?

• A61B 6/04 - Positioning of patientsTiltable beds or the like

Abstract

Methods, systems, and apparatuses are described for modeling and classifying one or more model outputs as they relate to one or more candidate objects.

IPC Classes  ?

• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G06T 7/00 - Image analysis
• G06T 7/12 - Edge-based segmentation
• G06T 7/20 - Analysis of motion
• G06T 17/20 - Wire-frame description, e.g. polygonalisation or tessellation

Abstract

A method and systems for automatically determining and classifying quality control issues in slide image data are disclosed. A method includes receiving image data associated with a slide, and determining, based on the image data, information associated with one or more pixels in the image data. The method further includes determining based on the information associated with the one or more pixels in the image data, one or more quality control indications; and identifying, based on the one or more quality control indications, the slide as quality control deficient.

IPC Classes  ?

• G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
• G06T 7/00 - Image analysis
• G06T 7/13 - Edge detection

Abstract

Disclosed are trimeric complexes comprising an uncleaved prefusion optimized gp140 env trimer. Disclosed are compositions comprising a trimeric complex, wherein the trimeric complex comprises an uncleaved prefusion optimized gp140 env trimer. Disclosed are methods of inducing an immune response against HIV in a subject comprising administering one or more of the disclosed compositions to a subject in need thereof. Disclosed are methods of generating neutralizing antibodies (nAbs) to HIV in a subject comprising administering one or more of the disclosed compositions to a subject in need thereof. Disclosed are method of treating a subject infected with HIV comprising administering one or more of the disclosed compositions to a subject in need thereof. Disclosed are methods of inducing an immune response against HIV in a subject comprise administering a composition or vaccine comprising a trimeric complex, wherein the trimeric complex comprises an uncleaved prefusion optimized gp140 env trimer, as disclosed herein, in combination with administering a composition or vaccine comprising a nucleic acid construct, wherein the nucleic acid construct comprises a nucleic acid sequence that encodes for a polypeptide comprising an HIV-1 derived V1V2 domain and a trimer-forming scaffold.

IPC Classes  ?

• A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/18 - Antivirals for RNA viruses for HIV
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

The present disclosure relates to compounds, compositions, and methods for inhibiting Nox4 signaling. Also described are methods of treating fibrotic disorders (e.g, pulmonary fibrosis, heart fibrosis, kidney fibrosis, liver fibrosis, skin fibrosis, mediastinal fibrosis, retroperitoneal cavity fibrosis, bone marrow fibrosis, scleroderma or systemic sclerosis), acute respiratory distress syndrome (ARDS), and cancer (e.g, a sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, non-small cell lung carcinoma, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell neoplasm (myeloma)) using the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/33 - Heterocyclic compounds

Abstract

A lid for inactivating or otherwise deterring use of a medication in a medication container is disclosed. The lid has a body that is configured to be secured to the medication container. A receptacle has a deterrent composition therein. A sharp object is movable from a first position that is spaced from the receptacle to a second position in which the sharp object punctures the receptacle. A controller is operable to: initiate a timer having a set duration; and cause the sharp object to move from the first position to the second position upon expiration of the set duration of the timer. A compression assembly applies a pressure to the receptacle so that, when the sharp object moves from the first position to the second position to puncture the receptacle, the compression assembly facilitates flow of the deterrent composition from the receptacle.

IPC Classes  ?

• A61J 7/04 - Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
• A61J 1/03 - Containers specially adapted for medical or pharmaceutical purposes for pills or tablets

Abstract

A cuff for providing vagus nerve stimulation to a subject having an esophagus is disclosed. The cuff includes a helical body that is configured to wrap around at least a portion of the esophagus of the subject, the helical body having an inner surface, the inner surface having a length and a width. The inner surface defines an interior space that is configured to receive the esophagus. A first electrode is coupled to the helical body. At least one additional electrode is coupled to the helical body. The at least one additional electrode is configured to provide a polarity opposite of the first electrode.

IPC Classes  ?

• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

e.ge.g.e.g., a sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, non-small cell lung carcinoma, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, plasma cell neoplasm (myeloma)) using the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 35/00 - Antineoplastic agents
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

The present disclosure relates to compounds, compositions, and methods for inhibiting Nox4 signaling. Also described are methods of treating fibrotic disorders (e.g., pulmonary fibrosis, heart fibrosis, kidney fibrosis, liver fibrosis, skin fibrosis, mediastinal fibrosis, retroperitoneal cavity fibrosis, bone marrow fibrosis, scleroderma or systemic sclerosis) and acute respiratory distress syndrome (ARDS) using the disclosed compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/33 - Heterocyclic compounds

Abstract

The present disclosure relates to techniques for fusing deep learning-based image reconstructions with noisy image measurements with provable assurances that the resulting improved image does not remove the information content of the original noisy measurements or image. Particularly, aspects are directed to obtaining measurement data from an imaging modality, generating a base image by solving an optimization problem using at least a signal model and the measurement data, generating, using a deep-learning model, a predicted image based on the measurement data, selecting a modified operator based on the signal model, generating an enhanced image by solving the modified optimization problem using at least: (i) the base image or the measurement data, (ii) the signal model, (iii) the predicted image, and (iv) the modified operator, and outputting the enhanced image.

IPC Classes  ?

• G06T 11/00 - 2D [Two Dimensional] image generation
• G06T 11/60 - Editing figures and textCombining figures or text
• G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

An apparatus comprises a magnetic stimulation coil having a central axis and one or more capacitive sensors. The one or more capacitive sensors can be configured to contact a target and/or a target area and/or a target surface. Processing circuitry can be configured to detect the contact between at least one capacitive sensor and, for example, the target surface. One or more range sensors can be spaced from the central axis of the magnetic stimulation coil. A display can be configured to display a location corresponding to the contact between the at least one capacitive sensor and the target area, a distance between at least one range sensor and the target surface, and a rotation of a coil with respect to a reference angle.

IPC Classes  ?

• A61N 2/02 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
• A61N 2/00 - Magnetotherapy

Abstract

Disclosed herein are compositions comprising or consisting of Lactobacillus acidophilus and one or more prebiotics. Also disclosed herein are methods for treating osteoarthritis, inhibiting or preventing cartilage degeneration, and reducing or inhibiting pain-associated depression in subjects with joint pain with compositions comprising or consisting of Lactobacillus acidophilus and one or more prebiotics.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 31/733 - Fructosans, e.g. inulin

Abstract

Disclosed are salts of benzoic acid and prodrugs thereof for slowing the progression of or reducing the severity of a symptom associated with a nervous system injury in a subject.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

An electrode for providing non-invasive genital stimulation for continence of a subject is disclosed. The electrode includes a body and a plurality of projections extending from the body. The body and projections are unitarily formed from a dry, nonmetallic conductive material. The body and projections can be formed by dip molding.

IPC Classes  ?

• A61N 1/04 - Electrodes
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61F 5/48 - Devices for preventing wetting or pollution of the bed

Abstract

A method for detecting, diagnosing or screening for cognitive impairment in a subject includes a) positioning the subject in front of a screen, b) displaying a video to the subject on the screen, the video including a target that moves around a predefined closed perimeter of the screen, the target forming at least one revolution on the screen around the closed perimeter, c) tracking eye movement of at least one eye of the subject as the subject watches the video, d) analyzing eye movement of at least one eye of the subject, e) calculating a statistical test for eye movement of at least one eye of the subject as compared to a normal or mean eye movement, f) detecting, diagnosing or screening for an impairment based on the calculated statistical test, and g) providing a suitable clinical intervention based on the calculated statistical test.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• A61B 3/08 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing binocular or stereoscopic vision, e.g. strabismus
• A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
• A61B 5/03 - Measuring fluid pressure within the body other than blood pressure, e.g. cerebral pressure